KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Other Accumulated Expenses (2016 - 2025)

Novavax (NVAX) has 13 years of Other Accumulated Expenses data on record, last reported at $137.8 million in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 37.26% year-over-year to $137.8 million; the TTM value through Dec 2025 reached $137.8 million, down 37.26%, while the annual FY2025 figure was $137.8 million, 37.26% down from the prior year.
  • Other Accumulated Expenses reached $137.8 million in Q4 2025 per NVAX's latest filing, roughly flat from $138.3 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $930.1 million in Q4 2022 and bottomed at $2.4 million in Q1 2021.
  • Average Other Accumulated Expenses over 5 years is $303.8 million, with a median of $151.3 million recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 4312.95% in 2022, then crashed 74.51% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $36.1 million in 2021, then surged by 2479.12% to $930.1 million in 2022, then dropped by 7.38% to $861.4 million in 2023, then tumbled by 74.51% to $219.6 million in 2024, then plummeted by 37.26% to $137.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $137.8 million in Q4 2025, $138.3 million in Q3 2025, and $132.5 million in Q2 2025.